Wednesday, November 12, 2008

Online : Express Health care : India : Dr Lal Pathlabs


Dr Lal Pathlabs

Dr Lal Path Labs (LPL) a chain of pathological laboratories headquartered in New Delhi, with labs in Mumbai, Gurgaon, Noida, Kanpur, Chandigarh, Ludhiana and Jammu, has a countrywide network of collection centres. LPL was established in 1949 by the late Dr S K Lal, one of the pioneers in the field of pathology. This is a chain of 35 labs and 600 collection centres all across India. The lab today offers a comprehensive test menu covering the entire diagnostics range with 1650 tests.

Growth Path

The annual turnover of the company for this year is Rs 150 crore. LPL carries the highest number of tests in the areas of pathology, cardiology and radiology. The company has been managing the lab activities for Vishesh Hospital, Indore from the past one year and it would soon be looking after the lab activities for Jindal Hospital in Isar, Punjab by November, 2008. The lab is planning to expand their test menu, so the new HIV tests and new TB tests are some of the tests that will be conducted at LPL by end of October 2008. "The company follows a Plan-Do-Check-Act (PDCA) cycle to continuously improve and better customer service which is the guiding principle," informs Dr OP Manchanda, CEO, Dr Lal PathLabs. The company also has its collections centres in Nepal and Bangladesh.
 
 

Tuesday, November 11, 2008

Online Business News: The Hindu : Diagnostics services business : India : Metropolis' investment plans

Company proposes to raise Rs. 35 cr. as private equity


  • To set up two laboratories in South Africa
  • Plans radiology division in the Chennai facility

  • CHENNAI: Metropolis Health Services (I) Ltd, which has a network of diagnostic laboratories in India and abroad, plans to invest Rs. 100 crore during the current year for its expansion programmes, according to G. S. K. Velu, Managing Director.

    With 18 laboratories in India, three in Dubai and one in Sri Lanka, Mumbai-headquartered Metropolis plans to set up two laboratories in South Africa and one each in Thailand and Kuwait by the end of the second quarter of the year. Besides, it is in the process of finalising labs in Kolkata and Hyderabad, Mr. Velu told The Hindu.

    Of the total investment, Rs. 85 crore would be used for either acquiring units or setting up green field projects within the country and abroad.

    The balance amount would be used for clinical trials. The company proposed to raise Rs. 35 crore as private equity from ICICI and the balance through debts.

     
     

     
    TopOfBlogs